Search research articles
Contact Us
Filters
Showing results (151-160 of 184) with videos related to
Page
of 19
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 11, 2012
Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion
Fiona Simpkins, Andrea Papadia, Charles Kunos, et al.
Gynecologic Oncology
|
October 31, 2009
Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence
Nabila Rasool, Amanda Nickles Fader, Leigh Seamon, et al.
Gynecologic Oncology
|
June 4, 2021
Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Laura M Chambers, Julia Chalif, Meng Yao, et al.
Gynecologic Oncology
|
August 14, 2012
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer
Kimberly K Leslie, Michael W Sill, Heather A Lankes, et al.
Gynecologic Oncology
|
September 11, 2012
A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study
Kathleen N Moore, Michael W Sill, David S Miller, et al.
NPJ Precision Oncology
|
July 19, 2023
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition
Hussein Al-Sudani, Ying Ni, Philip Jones, et al.
Gynecologic Oncology
|
October 4, 2016
Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
Peter G Rose, James J Java, Mark A Morgan, et al.
Gynecologic Oncology
|
November 13, 2007
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary
Kathleen N Moore, Katherine M Moxley, Amanda Nickles Fader, et al.
Gynecologic Oncology
|
January 31, 2014
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube
Thomas J Herzog, Bradley J Monk, Peter G Rose, et al.
Journal of Ovarian Research
|
April 23, 2021
Pretreatment with LCK inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors
Katie K Crean-Tate, Chad Braley, Goutam Dey, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 184) with videos related to
Sort By:
Page
of 19
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 11, 2012
Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion
Fiona Simpkins, Andrea Papadia, Charles Kunos, et al.
Gynecologic Oncology
|
October 31, 2009
Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence
Nabila Rasool, Amanda Nickles Fader, Leigh Seamon, et al.
Gynecologic Oncology
|
June 4, 2021
Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Laura M Chambers, Julia Chalif, Meng Yao, et al.
Gynecologic Oncology
|
August 14, 2012
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer
Kimberly K Leslie, Michael W Sill, Heather A Lankes, et al.
Gynecologic Oncology
|
September 11, 2012
A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study
Kathleen N Moore, Michael W Sill, David S Miller, et al.
NPJ Precision Oncology
|
July 19, 2023
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition
Hussein Al-Sudani, Ying Ni, Philip Jones, et al.
Gynecologic Oncology
|
October 4, 2016
Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
Peter G Rose, James J Java, Mark A Morgan, et al.
Gynecologic Oncology
|
November 13, 2007
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary
Kathleen N Moore, Katherine M Moxley, Amanda Nickles Fader, et al.
Gynecologic Oncology
|
January 31, 2014
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube
Thomas J Herzog, Bradley J Monk, Peter G Rose, et al.
Journal of Ovarian Research
|
April 23, 2021
Pretreatment with LCK inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors
Katie K Crean-Tate, Chad Braley, Goutam Dey, et al.
Page
of 19